Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Barriers to initiation of antiretrovirals during antituberculosis therapy in Africa.

Pepper DJ, Marais S, Wilkinson RJ, Bhaijee F, De Azevedo V, Meintjes G.

PLoS One. 2011 May 12;6(5):e19484. doi: 10.1371/journal.pone.0019484.

2.

The effect of complete integration of HIV and TB services on time to initiation of antiretroviral therapy: a before-after study.

Kerschberger B, Hilderbrand K, Boulle AM, Coetzee D, Goemaere E, De Azevedo V, Van Cutsem G.

PLoS One. 2012;7(10):e46988. doi: 10.1371/journal.pone.0046988. Epub 2012 Oct 5.

4.

Antiretroviral therapy initiation during tuberculosis treatment and HIV-RNA and CD4 T-lymphocyte responses.

Takuva S, Westreich D, Menezes CN, McNamara L, Sanne I, Page-Shipp L, Maskew M.

Int J Tuberc Lung Dis. 2012 Oct;16(10):1358-64. doi: 10.5588/ijtld.11.0769. Epub 2012 Aug 3.

5.

Antiretroviral treatment uptake in patients with HIV-associated TB attending co-located TB and ART services.

Nglazi MD, Kaplan R, Caldwell J, Peton N, Lawn SD, Wood R, Bekker LG.

S Afr Med J. 2012 Oct 22;102(12):936-9. doi: 10.7196/samj.6024.

6.

Reasons for accepting or refusing HIV services among tuberculosis patients at a TB-HIV integration clinic in Malawi.

Kumwenda M, Tom S, Chan AK, Mwinjiwa E, Sodhi S, Joshua M, van Lettow M.

Int J Tuberc Lung Dis. 2011 Dec;15(12):1663-9. doi: 10.5588/ijtld.10.0741.

PMID:
22118175
7.

Impact of ART on TB case fatality stratified by CD4 count for HIV-positive TB patients in Cape Town, South Africa (2009-2011).

Kaplan R, Caldwell J, Middelkoop K, Bekker LG, Wood R.

J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):487-94. doi: 10.1097/QAI.0000000000000201.

8.

Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors.

Pepper DJ, Marais S, Wilkinson RJ, Bhaijee F, Maartens G, McIlleron H, De Azevedo V, Cox H, McDermid C, Sokhela S, Patel J, Meintjes G.

BMC Infect Dis. 2010 Mar 30;10:83. doi: 10.1186/1471-2334-10-83.

9.

Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database.

Han SH, Zhou J, Lee MP, Zhao H, Chen YM, Kumarasamy N, Pujari S, Lee C, Omar SF, Ditangco R, Phanuphak N, Kiertiburanakul S, Chaiwarith R, Merati TP, Yunihastuti E, Tanuma J, Saphonn V, Sohn AH, Choi JY; TREAT Asia HIV Observational Database.

HIV Med. 2014 Feb;15(2):77-85. doi: 10.1111/hiv.12073. Epub 2013 Aug 28.

10.

Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy.

Nagu TJ, Aboud S, Mwiru R, Matee MI, Rao M, Fawzi WW, Zumla A, Maeurer MJ, Mugusi F.

Int J Infect Dis. 2017 Mar;56:39-44. doi: 10.1016/j.ijid.2017.01.023. Epub 2017 Feb 1. Review.

11.

Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.

Schnippel K, Berhanu RH, Black A, Firnhaber C, Maitisa N, Evans D, Sinanovic E.

BMC Infect Dis. 2016 Oct 21;16(1):593.

12.

Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township.

Lawn SD, Campbell L, Kaplan R, Little F, Morrow C, Wood R; IeDEA-Southern Africa.

BMC Infect Dis. 2011 Sep 30;11:258. doi: 10.1186/1471-2334-11-258.

14.

Integration and task shifting for TB/HIV care and treatment in highly resource-scarce settings: one size may not fit all.

Van Rie A, Patel MR, Nana M, Vanden Driessche K, Tabala M, Yotebieng M, Behets F.

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e110-7. doi: 10.1097/01.qai.0000434954.65620.f3.

PMID:
24091692
15.

Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial.

Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, Borand L, Prak N, Kim C, Lak KK, Hak C, Dim B, Sok T, Delfraissy JF, Goldfeld AE, Blanc FX; CAMELIA (ANRS 1295-CIPRA KH001) Study Team.

Clin Infect Dis. 2014 Aug 1;59(3):435-45. doi: 10.1093/cid/ciu283. Epub 2014 Apr 23.

16.

Assessment at antiretroviral clinics during TB treatment reduces loss to follow-up among HIV-infected patients.

Pepper DJ, Marais S, Bhaijee F, Wilkinson RJ, De Azevedo V, Meintjes G.

PLoS One. 2012;7(6):e37634. doi: 10.1371/journal.pone.0037634. Epub 2012 Jun 18.

17.

Time to initiation of antiretroviral therapy among patients with HIV-associated tuberculosis in Cape Town, South Africa.

Lawn SD, Campbell L, Kaplan R, Boulle A, Cornell M, Kerschberger B, Morrow C, Little F, Egger M, Wood R; International Epidemiological Databases to Evaluate AIDS-Southern Africa.

J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):136-40. doi: 10.1097/QAI.0b013e3182199ee9.

18.

Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success.

Daniels JF, Khogali M, Mohr E, Cox V, Moyo S, Edginton M, Hinderaker SG, Meintjes G, Hughes J, De Azevedo V, van Cutsem G, Cox HS.

PLoS One. 2015 Nov 10;10(11):e0142873. doi: 10.1371/journal.pone.0142873. eCollection 2015.

19.

Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment.

Sinha S, Shekhar RC, Singh G, Shah N, Ahmad H, Kumar N, Sharma SK, Samantaray JC, Ranjan S, Ekka M, Sreenivas V, Mitsuyasu RT.

BMC Infect Dis. 2012 Jul 31;12:168.

20.

Active tuberculosis is associated with worse clinical outcomes in HIV-infected African patients on antiretroviral therapy.

Siika AM, Yiannoutsos CT, Wools-Kaloustian KK, Musick BS, Mwangi AW, Diero LO, Kimaiyo SN, Tierney WM, Carter JE.

PLoS One. 2013;8(1):e53022. doi: 10.1371/journal.pone.0053022. Epub 2013 Jan 2.

Supplemental Content

Support Center